(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance

(PQ1) 调节林奇综合征外显率的适应性免疫和微生物机制

基本信息

  • 批准号:
    10229450
  • 负责人:
  • 金额:
    $ 50.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-04 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

This study focuses on Provocative Question 1: What molecular mechanisms influence penetrance in individuals who inherit a cancer susceptibility gene? Lynch syndrome is a genetic disease predisposing to colorectal (CRC) and other cancers that affects >1 million Americans. Germline mutations in DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 cause MMR deficiency (dMMR) and Lynch syndrome. Lynch syndrome CRCs have greatly elevated missense and small in/del frameshift mutation rates. Lynch syndrome has incomplete disease penetrance that varies widely. Here we will mechanistically elucidate two important questions about Lynch syndrome CRC penetrance. First, immune checkpoint blockade studies have revealed important roles for adaptive immunity against tumor mutation associated neoantigens (MANAs) in late stage and metastatic Lynch syndrome /dMMR malignancies. However, in the setting of pre-malignancy and early-stage CRCs, where the MANA burden is much lower, does adaptive immunity suppress Lynch syndrome penetrance? Second, the microbiota Fusobacterium nucleatum (F. nucleatum) is consistently associated with increased CRC risk. For Lynch syndrome CRCs, what are the mechanisms through which F. nucleatum promotes penetrance? In part these questions remain unanswered because Lynch syndrome mouse models develop few CRCs. To elucidate the mechanisms influencing Lynch syndrome CRC penetrance, we have developed the first robust mouse Lynch syndrome CRC model. In Aim 1 we will elucidate the roles of adaptive immunity mechanisms to reduce mouse - Lynch syndrome CRC penetrance. We will test hypotheses that neoantigen vaccination reduces overall mouse Lynch syndrome CRC penetrance, and specifically for CRCs that arise from Lgr5+ cancer stem cells. In Aim 2 we will elucidate mechanisms of F. nucleatum to promote Lynch syndrome CRC penetrance. We will test hypotheses that F. nucleatum promotes IL17A driven Lynch Syndrome Lgr5+ cancer stem cell proliferation, that F. nucleatum mono-association promotes mouse Lynch syndrome CRC penetrance, and that vaccination with F. nucleatum antigens reduces colonization and CRC penetrance in Lynch Syndrome mice. Overall these studies will use state-of-the-art tools to elucidate adaptive immune mechanisms influencing Lynch syndrome CRC penetrance.
本研究的重点是激发性问题1:什么分子机制影响外显率 遗传了癌症易感基因的个体 Lynch综合征是一种易患结直肠癌(CRC)和其他癌症的遗传性疾病,影响>1 百万美国人。DNA错配修复(MMR)基因MLH 1、MSH 2、MSH 6和PMS 2的种系突变 引起MMR缺乏症(dMMR)和Lynch综合征。Lynch综合征CRCs的错义率显著升高 和小的in/del移码突变率。Lynch综合征的疾病外显率不完全, 广泛地。在这里,我们将从机制上阐明两个重要的问题林奇综合征CRC 外显率首先,免疫检查点阻断研究揭示了获得性免疫的重要作用 晚期和转移性Lynch综合征中抗肿瘤突变相关新抗原(MANAs)/dMMR 恶性肿瘤。然而,在恶性肿瘤前期和早期CRC的情况下,MANA负荷是 低得多,获得性免疫是否抑制Lynch综合征外显率?二、微生物群 具核梭杆菌(Fusobacterium nucleatum, F.细胞核)与CRC风险增加一致相关。对林奇 综合征CRCs,通过什么机制,F.细胞核促进外显?其中一部分 由于Lynch综合征小鼠模型几乎不产生CRCs,因此问题仍未得到解答。阐明本 影响Lynch综合征CRC外显率的机制,我们开发了第一个健壮的小鼠Lynch 综合征CRC模型。在目标1中,我们将阐明获得性免疫机制在减少小鼠-T细胞亚群中的作用。 Lynch综合征CRC外显率我们将检验新抗原疫苗接种降低小鼠总体免疫力假设 Lynch综合征CRC外显率,特别是来自Lgr 5+癌症干细胞的CRC。在目标2中 我们将阐明F.核仁区促进Lynch综合征CRC外显率。我们将测试 假设F. nucleatum促进IL 17 A驱动的Lynch综合征Lgr 5+癌干细胞增殖, 即F.细胞核单结合促进小鼠Lynch综合征CRC外显率,且接种 与F.细胞核抗原降低Lynch综合征小鼠中的定居和CRC外显率。总的来说这些 研究将使用最先进的工具来阐明影响林奇综合征的适应性免疫机制 CRC外显率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven M Lipkin其他文献

Kinetics of cancer: a method to test hypotheses of genetic causation
癌症动力学:检验遗传因果假设的方法
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Steven A Frank;Peng;Steven M Lipkin
  • 通讯作者:
    Steven M Lipkin

Steven M Lipkin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven M Lipkin', 18)}}的其他基金

Lynch Vaccine
林奇疫苗
  • 批准号:
    10505678
  • 财政年份:
    2022
  • 资助金额:
    $ 50.32万
  • 项目类别:
CAP-IT CRI U54 ADMINISTRATIVE CORE
CAP-IT CRI U54 管理核心
  • 批准号:
    10505676
  • 财政年份:
    2022
  • 资助金额:
    $ 50.32万
  • 项目类别:
Cancer Immune-Interception for Lynch Syndrome
林奇综合征的癌症免疫拦截
  • 批准号:
    10491665
  • 财政年份:
    2021
  • 资助金额:
    $ 50.32万
  • 项目类别:
Cancer Immune-Interception for Lynch Syndrome
林奇综合征的癌症免疫拦截
  • 批准号:
    10706565
  • 财政年份:
    2021
  • 资助金额:
    $ 50.32万
  • 项目类别:
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer
阐明 MALAT1 体细胞驱动突变在结直肠癌中的作用
  • 批准号:
    10307526
  • 财政年份:
    2018
  • 资助金额:
    $ 50.32万
  • 项目类别:
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer
阐明 MALAT1 体细胞驱动突变在结直肠癌中的作用
  • 批准号:
    10056203
  • 财政年份:
    2018
  • 资助金额:
    $ 50.32万
  • 项目类别:
Neoantigen Vaccination for Lynch Syndrome Immunoprevention
林奇综合征免疫预防的新抗原疫苗接种
  • 批准号:
    9789215
  • 财政年份:
    2018
  • 资助金额:
    $ 50.32万
  • 项目类别:
Neoantigen Vaccination for Lynch Syndrome Immunoprevention
林奇综合征免疫预防的新抗原疫苗接种
  • 批准号:
    10478171
  • 财政年份:
    2018
  • 资助金额:
    $ 50.32万
  • 项目类别:
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer
阐明 MALAT1 体细胞驱动突变在结直肠癌中的作用
  • 批准号:
    10532219
  • 财政年份:
    2018
  • 资助金额:
    $ 50.32万
  • 项目类别:
Neoantigen Vaccination for Lynch Syndrome Immunoprevention
林奇综合征免疫预防的新抗原疫苗接种
  • 批准号:
    10240627
  • 财政年份:
    2018
  • 资助金额:
    $ 50.32万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.32万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了